Immunotherapy in patients with locally advanced esophageal carcinoma: ASCO treatment of locally advanced esophageal carcinoma Guideline Rapid Recommendation Update

Immunotherapy in patients with locally advanced esophageal carcinoma: ASCO treatment of locally advanced esophageal carcinoma Guideline Rapid Recommendation Update - American Society of Clinical Oncology (ASCO)

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.

Background: In 2020, ASCO published a guideline on the management of locally advanced esophageal cancer. The CheckMate 577 double-blind, placebo-controlled, phase III randomized controlled trial (RCT) was recently reported, evaluating the efficacy of the addition of the checkpoint inhibitor nivolumab following neoadjuvant chemoradiotherapy (CRT) and surgery in patients with stage II/III esophageal carcinoma with residual disease (ie, patients who had viable disease in the surgical resection specimen after receiving CRT). The CheckMate 577 results provided a strong signal indicating the need to update the 2020 guideline recommendations.


Read full Guideline